Program
CDK2 Inhibitor INCB123667
Its studies are mostly in Ovarian Neoplasms · Kidney Failure, Chronic · Hepatic Insufficiency, led by Incyte.
Furthest: phase 3, since Oct 6, 20257 company-led studies, 5 open or runningNext primary completion: Jan 4, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyte | 75 open or running | phase 3since Oct 6, 2025 | Mar 27, 2025 | Jan 4, 2027phase 1 · NCT07559396 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 27, 2025First study: phase 1 study in Healthy ParticipantsFirst studyNCT06909162 · 51 enrolled · United States
- Jun 9, 2025Phase 2 study in Ovarian NeoplasmsNCT07023627 · 160 planned · United States, Australia, Belgium and more
- Oct 6, 2025Phase 3 study in Ovarian NeoplasmsNCT07214779 · 466 planned · United States, Australia, Belgium and more
- Oct 16, 2025Phase 1 study in Healthy ParticipantsNCT07218744 · 9 enrolled · United States
- Apr 24, 20262 phase 1 studiesNCT07559474, NCT07559396
- Aug 26, 2026Phase 3 study in Ovarian NeoplasmsNCT07797283 · 590 planned
Ahead
- Jan 4, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07559396
- Apr 13, 2027Primary completion: phase 1 study in Hepatic InsufficiencyNCT07559474
- Apr 27, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT07023627
- Nov 15, 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT07214779
TargetBeta
CDK2 →read by rule
“An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), ”NCIt, by rule
Other programs on CDK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| tegtociclib | Pfizer | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
| CDK2 Inhibitor AVZO-021rule | avenzo-therapeutics-inc | phase 2 | 2 |
| CDK2 Inhibitor ECI830 | Novartis | phase 2 | 1 |
| CDK2 Degrader BG-75098rule | BeOne Medicines | phase 1 | 1 |
| CG-7321rule | chengdu-cynogen-bio-pharmaceutical-tech-co-ltd | phase 1 | 1 |
| nkt5097 cdk2rule | nikang-therapeutics-inc | phase 1 | 1 |
| ZE94-0605rule | eilean-therapeutics | phase 1 | 1 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07797283Ovarian Neoplasms | 3 | Not yet recruiting | May 1, 2032 | 590 |
| NCT07559474Hepatic Insufficiency · United States | 1 | Recruiting | Apr 13, 2027 | 16 |
| NCT07559396Renal Insufficiency · United States | 1 | Recruiting | Jan 4, 2027 | 16 |
| NCT07218744Healthy Participants · United States | 1 | Completed | Dec 10, 2025 | 9 |
| NCT07214779Ovarian Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | Nov 15, 2028 | 466 |
| NCT07023627Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Apr 27, 2027 | 160 |
| NCT06909162Healthy Participants · United States | 1 | Completed | May 17, 2026 | 51 |
How it is read
Names in the registry
- “INCB123667”, 7 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 3 studies
- Kidney Failure, Chronic, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.